{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:09:27Z","timestamp":1792177767828,"version":"4.4.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T00:00:00Z","timestamp":1559260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002975","name":"Dainippon Sumitomo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.jns.2019.05.028","type":"journal-article","created":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T11:07:22Z","timestamp":1558696042000},"page":"145-152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Comparison of zonisamide with non-levodopa, anti-Parkinson's disease drugs in the incidence of Parkinson's disease-relevant symptoms"],"prefix":"10.1016","volume":"402","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8982-7885","authenticated-orcid":false,"given":"Hirotaka","family":"Iwaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Tagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2981-1013","authenticated-orcid":false,"given":"Masahiro","family":"Nomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2019.05.028_bb0005","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2019.05.028_bb0010","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/mds.26077","article-title":"The onset of nonmotor symptoms in Parkinson's disease (the ONSET PD study)","volume":"30","author":"Pont-Sunyer","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2019.05.028_bb0015","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/j.parkreldis.2015.09.004","article-title":"Non-motor symptoms in Parkinson's disease","volume":"22","author":"Pfeiffer","year":"2016","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2019.05.028_bb0020","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10072-017-3154-8","article-title":"Cognitive and behavioral disorders in Parkinson's disease: an update. I: cognitive impairments","volume":"39","author":"Papagno","year":"2018","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.jns.2019.05.028_bb0025","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10072-017-3155-7","article-title":"Cognitive and behavioral disorders in Parkinson's disease: an update. II: behavioral disorders","volume":"39","author":"Trojano","year":"2018","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.jns.2019.05.028_bb0030","series-title":"Igaku Shoin, Tokyo","first-page":"2018","author":"Japanese Society of Neurology Task Force on Practice Guidelines for Parkinson's Disease","year":"2018"},{"key":"10.1016\/j.jns.2019.05.028_bb0035","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0168-0102(01)00298-X","article-title":"Zonisamide has beneficial effects on Parkinson's disease patients","volume":"41","author":"Murata","year":"2001","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.jns.2019.05.028_bb0040","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1212\/01.wnl.0000250236.75053.16","article-title":"Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study","volume":"68","author":"Murata","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2019.05.028_bb0045","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/ncn3.12026","article-title":"Randomized placebo-controlled trial of zonisamide in patients with Parkinson's disease","volume":"4","author":"Murata","year":"2016","journal-title":"Neurol. Clin. Neurosci."},{"key":"10.1016\/j.jns.2019.05.028_bb0050","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.expneurol.2009.11.018","article-title":"The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance","volume":"221","author":"Sonsalla","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.jns.2019.05.028_bb0055","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1059-1311(96)80104-X","article-title":"Mechanisms of T-type calcium channel blockade by zonisamide","volume":"5","author":"Kito","year":"1996","journal-title":"Seizure"},{"key":"10.1016\/j.jns.2019.05.028_bb0060","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0920-1211(95)00078-X","article-title":"Effects of zonisamide on dopaminergic system","volume":"22","author":"Okada","year":"1995","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.jns.2019.05.028_bb0065","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/ana.21885","article-title":"Neuroprotective effects of zonisamide target astrocyte","volume":"67","author":"Asanuma","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2019.05.028_bb0070","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.brainres.2011.02.017","article-title":"Zonisamide-induced long-lasting recovery of dopaminergic neurons from MPTP-toxicity","volume":"1384","author":"Choudhury","year":"2011","journal-title":"Brain Res."},{"key":"10.1016\/j.jns.2019.05.028_bb0075","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jns.2018.05.013","article-title":"Zonisamide cotreatment delays striatal dopamine transporter reduction in Parkinson disease: a retrospective, observational cohort study","volume":"391","author":"Ikeda","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2019.05.028_bb0080","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1517\/14656566.8.1.111","article-title":"Zonisamide for bipolar depression","volume":"8","author":"Wilson","year":"2007","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.jns.2019.05.028_bb0085","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1007\/s00415-010-5603-7","article-title":"Zonisamide in managing impulse control disorders in Parkinson's disease","volume":"257","author":"Bermejo","year":"2010","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2019.05.028_bb0090","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1212\/01.wnl.0000306632.43729.24","article-title":"Dementia and survival in Parkinson disease: a 12-year population study","volume":"70","author":"Buter","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2019.05.028_bb0095","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/mds.21956","article-title":"The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years","volume":"23","author":"Hely","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2019.05.028_bb0100","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/brain\/awq059","article-title":"Relationships between age and late progression of Parkinson's disease: a clinico-pathological study","volume":"133","author":"Kempster","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.jns.2019.05.028_bb0105","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.brainres.2005.05.005","article-title":"Lithium differs from anticonvulsant mood stabilizers in prefrontal cortical and accumbal dopamine release: role of 5-HT1A receptor agonism","volume":"1049","author":"Ichikawa","year":"2005","journal-title":"Brain Res."},{"key":"10.1016\/j.jns.2019.05.028_bb0110","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.biopsych.2014.09.013","article-title":"The cognition-enhancing effects of psychostimulants involve direct action in the prefrontal cortex","volume":"77","author":"Spencer","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jns.2019.05.028_bb0115","first-page":"CD003735","article-title":"Anticholinergics for symptomatic management of Parkinson's disease","volume":"2","author":"Katzenschlager","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jns.2019.05.028_bb0120","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/sj.npp.1301227","article-title":"Tolcapone improves cognition and cortical information processing in normal human subjects","volume":"32","author":"Apud","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jns.2019.05.028_bb0125","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.biopsych.2009.07.008","article-title":"Tolcapone effects on gating,working memory, and mood interact with the synonymous catechol-O-methyltransferase rs4818c\/g polymorphism","volume":"66","author":"Roussos","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jns.2019.05.028_bb0130","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s702-002-8235-5","article-title":"The visuo-cognitive and motor effect of amantadine in non-Caucasian patients with Parkinson's disease. A clinical and electrophysiological study","volume":"109","author":"Bandini","year":"2002","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.jns.2019.05.028_bb0135","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/ncpneuro0322","article-title":"Can amantadine therapy delay the onset of dementia in Parkinson's disease?","volume":"2","author":"Rajput","year":"2006","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"10.1016\/j.jns.2019.05.028_bb0140","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2147\/NSS.S18897","article-title":"Sleep disturbances in Parkinson's disease patients and management options","volume":"3","author":"Claassen","year":"2011","journal-title":"Nat. Sci. Sleep"},{"key":"10.1016\/j.jns.2019.05.028_bb0145","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/mds.10242","article-title":"Microstructure of the non-rapid eye movement sleep electroencephalogram in patients with newly diagnosed Parkinson's disease: effects of dopaminergic treatment","volume":"17","author":"Brunner","year":"2002","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2019.05.028_bb0150","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/0006-8993(93)91457-4","article-title":"The relative effects of selective M1 muscarinic antagonists on rapid eye movement sleep","volume":"608","author":"Zoltoski","year":"1993","journal-title":"Brain Res."},{"key":"10.1016\/j.jns.2019.05.028_bb0155","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1211\/0022357991772123","article-title":"Characterization of dopamine receptor subtypes involved in experimentally induced gastric and duodenal ulcers in rats","volume":"51","author":"Desai","year":"1999","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jns.2019.05.028_bb0160","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/01.jcp.0000239794.37073.70","article-title":"Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial","volume":"26","author":"Amsterdam","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jns.2019.05.028_bb0165","first-page":"527","article-title":"Transdermal selegiline for the treatment of major depressive disorder","volume":"3","author":"Lee","year":"2007","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jns.2019.05.028_bb0170","doi-asserted-by":"crossref","first-page":"440","DOI":"10.5535\/arm.2016.40.3.440","article-title":"The functional dysphagia scale is a useful tool for predicting aspiration pneumonia in patients with Parkinson disease","volume":"40","author":"Lee","year":"2016","journal-title":"Ann. Rehabil. Med."},{"key":"10.1016\/j.jns.2019.05.028_bb0175","doi-asserted-by":"crossref","first-page":"e99021","DOI":"10.1371\/journal.pone.0099021","article-title":"Prescribing pattern of anti-Parkinson drugs in Japan: a trend analysis from 2005 to 2010","volume":"9","author":"Nakaoka","year":"2014","journal-title":"PLoS One"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X19302448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X19302448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:47:27Z","timestamp":1758383247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X19302448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":35,"alternative-id":["S0022510X19302448"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2019.05.028","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of zonisamide with non-levodopa, anti-Parkinson's disease drugs in the incidence of Parkinson's disease-relevant symptoms","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2019.05.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}